Perceptive Advisors LLC increased its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 7.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,151,589 shares of the company’s stock after purchasing an additional 360,000 shares during the period. Neurocrine Biosciences accounts for 13.2% of Perceptive Advisors LLC’s investment portfolio, making the stock its biggest position. Perceptive Advisors LLC owned about 5.82% of Neurocrine Biosciences worth $399,712,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. The Manufacturers Life Insurance Company grew its position in Neurocrine Biosciences by 7.8% during the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after acquiring an additional 193 shares during the period. State Board of Administration of Florida Retirement System grew its position in Neurocrine Biosciences by 0.7% during the third quarter. State Board of Administration of Florida Retirement System now owns 120,426 shares of the company’s stock valued at $7,380,000 after acquiring an additional 810 shares during the period. Amalgamated Bank grew its position in Neurocrine Biosciences by 5.7% during the fourth quarter. Amalgamated Bank now owns 17,484 shares of the company’s stock valued at $1,357,000 after acquiring an additional 947 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Neurocrine Biosciences by 25.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,904 shares of the company’s stock valued at $458,000 after acquiring an additional 1,200 shares during the period. Finally, Swiss National Bank grew its position in Neurocrine Biosciences by 1.3% during the third quarter. Swiss National Bank now owns 147,300 shares of the company’s stock valued at $9,027,000 after acquiring an additional 1,900 shares during the period.
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) opened at $92.43 on Monday. Neurocrine Biosciences, Inc. has a 1 year low of $39.21 and a 1 year high of $92.98. The company has a debt-to-equity ratio of 0.99, a quick ratio of 10.20 and a current ratio of 10.20.
In related news, insider Darin Lippoldt sold 15,237 shares of the business’s stock in a transaction dated Thursday, December 28th. The stock was sold at an average price of $75.00, for a total value of $1,142,775.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Haig P. Bozigian sold 75,873 shares of the business’s stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $90.00, for a total value of $6,828,570.00. Following the completion of the transaction, the insider now owns 18,041 shares in the company, valued at approximately $1,623,690. The disclosure for this sale can be found here. In the last quarter, insiders sold 399,589 shares of company stock worth $32,443,795. Insiders own 4.80% of the company’s stock.
A number of equities research analysts have issued reports on the company. Oppenheimer set a $110.00 price target on Neurocrine Biosciences and gave the company a “buy” rating in a research report on Thursday, February 22nd. Needham & Company LLC reissued a “buy” rating and set a $110.00 price target (up previously from $95.00) on shares of Neurocrine Biosciences in a research report on Thursday, February 22nd. Leerink Swann boosted their price target on Neurocrine Biosciences from $90.00 to $96.00 and gave the company an “outperform” rating in a research report on Tuesday, February 20th. Deutsche Bank upped their target price on Neurocrine Biosciences to $97.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Finally, JPMorgan Chase & Co. upped their target price on Neurocrine Biosciences from $79.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 14th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $92.38.
WARNING: This report was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/03/12/neurocrine-biosciences-inc-nbix-shares-bought-by-perceptive-advisors-llc.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.